Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Frequently Asked Questions
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News

Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Phase 3 Meta-Analysis Data at the 32nd Congress of the European Society of Surgical Oncology

Sep 20, 2012

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease

Sep 18, 2012

Update: Navidea Biopharmaceuticals Change in Upcoming Investor Conference Schedule

Sep 11, 2012

Navidea Biopharmaceuticals Receives Complete Response Letter from FDA for Lymphoseek® NDA Due to Manufacturing Deficiencies

Sep 10, 2012

Navidea Biopharmaceuticals to Present at Upcoming Investor Conferences

Sep 5, 2012

Navidea Biopharmaceuticals Names Pharma Industry Veteran Cornelia Reininger, M.D., Ph.D., as Chief Medical Officer

Sep 5, 2012

Navidea Biopharmaceuticals Announces 2012 Annual Meeting Results

Aug 15, 2012

Navidea Biopharmaceuticals Announces Second Quarter 2012 Financial Results

Aug 6, 2012

Navidea Biopharmaceuticals Completes License for Parkinson's Disease Imaging Agent

Jul 31, 2012

Navidea Biopharmaceuticals Second Quarter 2012 Earnings and Business Update Conference Call Invitation

Jul 30, 2012
    • 1...
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    • 36
    © 2021 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    Twitter linkedin Facebook
    Privacy Policy Disclaimer Sitemap